(Q37662874)

21 August 2017

1 reference

title

Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial (English)

1 reference

21 August 2017

1 reference

E David Crawford

1

1 reference

21 August 2017

Gerald L Andriole

series ordinal

2

1 reference

21 August 2017

Michael Marberger

series ordinal

3

1 reference

21 August 2017

Roger S Rittmaster

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

29 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

75

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

502-509

1 reference

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Finasteride decreases the risk of prostatic intraepithelial neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Evidence for a biopsy derived grade artifact among larger prostate glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Outcome of sextant biopsy according to gland volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Prostate biopsy grading errors: a sampling problem?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Prostate volume and adverse prostate cancer features: fact not artifact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Hepatic resection: the last surgical frontier for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Prostate cancer prevention and finasteride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Estimating rates of true high-grade disease in the prostate cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Defining increased future risk for prostate cancer: evidence from a population based screening cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Quality of life and satisfaction with outcome among prostate-cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Systematic overview of cost-utility assessments in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

The cost of prostate cancer chemoprevention: a decision analysis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Chemoprevention of prostate cancer: agents and study designs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.099

10.1016/J.UROLOGY.2009.05.099

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference